These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 2316296)

  • 21. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of tamoxifen after chemotherapy in hormone receptor-positive, node-negative breast cancer.
    Panasci LC
    J Clin Oncol; 2006 May; 24(15):2392; author reply 2392. PubMed ID: 16710042
    [No Abstract]   [Full Text] [Related]  

  • 23. Adjuvant systemic treatment of resectable breast cancer: eleven years results of a monoinstitutional chemo-hormone-immunotherapy trial.
    Rosso R; Boccardo F; Brema F; Sertoli MR; Amoroso D; Bertelli G; Pronzato P
    Anticancer Res; 1989; 9(4):1153-6. PubMed ID: 2817796
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumor angiogenesis predicts clinical outcome of node-positive breast cancer patients treated with adjuvant hormone therapy or chemotherapy.
    Gasparini G; Barbareschi M; Boracchi P; Verderio P; Caffo O; Meli S; Dalla Palma P; Marubini E; Bevilacqua P
    Cancer J Sci Am; 1995; 1(2):131-41. PubMed ID: 9166466
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Is adjuvant therapy for older patients with node (+) early breast cancer cost-effective?
    Naeim A; Keeler EB
    Breast Cancer Res Treat; 2005 Nov; 94(2):95-103. PubMed ID: 16261407
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [A randomized controlled study comparing uracil-tegafur (UFT)+tamoxifen (UFT+TAM therapy) with cyclophosphamide+adriamycin+5-fluorouracil (CAF therapy) for women with stage I , II, or IIIa breast cancer with four or more involved nodes in the adjuvant setting].
    Inaji H; Sakai K; Oka T; Ozawa K; Saito Y; Senoo T; Taguchi T; Terasawa T; Nakao K; Mori T; Koyama H; Oshima A
    Gan To Kagaku Ryoho; 2006 Oct; 33(10):1423-9. PubMed ID: 17033231
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Breast carcinoma in accessory gland: a case report].
    Sivelli R; Del Rio P; Arcuri MF; Corcione L
    G Chir; 2002 May; 23(5):179-80. PubMed ID: 12228967
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adjuvant therapy in breast cancer.
    Robert NJ
    Obstet Gynecol Clin North Am; 1994 Dec; 21(4):693-707. PubMed ID: 7731642
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Benefits of adjuvant chemotherapy for breast cancer].
    Motomura K; Noguchi S; Inaji H; Koyama H
    Gan To Kagaku Ryoho; 1997 Aug; 24(10):1239-44. PubMed ID: 9279342
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Ablative hormone therapy and chemotherapy of metastatic breast cancer].
    Kasch R; Gerber B; Blaschke U
    Zentralbl Gynakol; 1989; 111(23):1584-7. PubMed ID: 2560303
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Short term results from GHRH analogue use in pre-menopausal breast cancer in Korea.
    Kim HJ; Lee JS; Park EH; Lim WS; Sei JY; Koh BS; Son BH; Ahn JH; Jeong KH; Kim SB; Ahn SH
    Eur J Surg Oncol; 2009 Sep; 35(9):936-41. PubMed ID: 19269125
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Thirty-year follow-up of chemo/hormonal therapy in node-positive breast cancer.
    Gordon NH; Silverman P; Lasheen W; Meinert J; Siminoff LA
    Breast Cancer Res Treat; 2007 May; 102(3):301-12. PubMed ID: 17033926
    [TBL] [Abstract][Full Text] [Related]  

  • 33. One more change of paradigm in breast cancer treatment. Postmastectomy radiotherapy for patients with one to three lymph node metastases?
    Sautter-Bihl ML; Sauer R
    Strahlenther Onkol; 2007 Jul; 183(7):357-9. PubMed ID: 17609867
    [No Abstract]   [Full Text] [Related]  

  • 34. Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy: results from five National Surgical Adjuvant Breast and Bowel Project randomized clinical trials.
    Taghian A; Jeong JH; Mamounas E; Anderson S; Bryant J; Deutsch M; Wolmark N
    J Clin Oncol; 2004 Nov; 22(21):4247-54. PubMed ID: 15452182
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Therapy studies of the Austrian Breast Cancer Group (ABC)].
    Jakesz R; Hausmaninger H; Samonigg H; Kubista E; Haider K; Mlineritsch B; Schmid M; Tausch C; Reiner G; Renner K; Stierer M; Jatzko G; Hofbauer F; Fridrik M; Schennach W; Sevelda P; Dadak C; Haid A; Scholz R; Lenzhofer P; Steindorfer P; Berger A; Mischinger HJ
    Zentralbl Chir; 1998; 123 Suppl 5():28-32. PubMed ID: 10063568
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [What is the benefit of adjuvant therapy in breast cancer?].
    Sauer H
    Fortschr Med; 1992 Nov; 110(30):16-8, 20. PubMed ID: 1468737
    [No Abstract]   [Full Text] [Related]  

  • 37. Intensification of adjuvant chemotherapy in patients with primary breast cancer and positive axillary nodes.
    Elias EG
    Md Med J; 1990 Dec; 39(12):1072-3. PubMed ID: 2266815
    [No Abstract]   [Full Text] [Related]  

  • 38. The NIH Consensus Development Conference on Adjuvant Chemotherapy for Breast Cancer--a commentary.
    Lippman ME
    Breast Cancer Res Treat; 1985; 6(3):195-200. PubMed ID: 3841498
    [No Abstract]   [Full Text] [Related]  

  • 39. Node-negative breast cancer: identifying those who should be spared adjuvant therapy.
    Oncology (Williston Park); 1990 Dec; 4(12):15-6. PubMed ID: 2149033
    [No Abstract]   [Full Text] [Related]  

  • 40. The present status of the adjuvant endocrine treatment.
    Jonat W; Maass H
    J Steroid Biochem; 1987; 27(1-3):499-502. PubMed ID: 3320540
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.